know how much that will help."
The most virulent critics even contend that the HapMap, as it is known, is nothing more than a full-employment enterprise for the big sequencing labs that might find themselves out of a job once the human genome is completed. "Is the HapMap being designed to satisfy the need [to get] another big project going?" asks Kenneth Weiss, an anthropologist and geneticist at Pennsylvania State University, University Park. Terwilliger minces no words. "The haplotype map is just an excuse for Lander and others to keep funding coming for large factories set up for the sequencing of the genome"-an idea Lander dismisses as sour grapes.
Despite these misgivings, the HapMap is well under way. In addition to NIH's $40 million, Canada recently kicked in CAN$9.5 million to fund one of its own researchers. Still some $60 million short, NHGRI will award the first grants this fall.
Unexpected architecture
The idea for the HapMap emerged from the gradual realization that the genome has a surprisingly structured architecture. Rather than being thrown together randomly, thousands of DNA bases-as well as patterns of Presented at a Cold Spring Harbor Laboratory meeting last spring, these findings initially generated skepticism. They began to win converts, however, and by summer, Collins made the HapMap-a map identifying haplotypes across the genome-a priority and was rustling up money and collaborators. In March, NIH began soliciting grants for the first of the map's two stages. The first will be to create haplotype maps of the genomes of three populations: those of northern and western European ancestry, Japanese and Chinese, and Yorubans. In the second stage, scientists will test whether the haplotypes they find in those very large populations also appear in about 10 others.
From SNPs to haplotypes
Haplotypes gained popularity as scientists realized that mining the genome was much tougher than expected. A few years ago, geneticists heralded single-nucleotide polymorphisms (SNPs) as the long-sought answer to finding genes involved in complex 64  63  62  61  60  59  58  57  56  55  54  53  52  51  50  49  48  47  46  45  44  43  42  41  40  39  38  37  36  35  34  33  32  31  30  29  28  27  26  25  24  23  22  21  20  19  18  17  16  15  14  13  12  11  10  9  8  7  6  5  4  3  2  1 www.sciencemag.org SCIENCE VOL 296 24 MAY 2002 diseases. Unlike cystic fibrosis or Huntington's disease, say, which are caused by a single genetic defect, complex diseases seem to arise from an uncertain mix of multiple gene mutations and environmental factors. Because each gene likely has a subtle effect, its "signal" is exceedingly tricky to detect.
SNPs are simply places where the genomes of different people vary by one base; they occur at least every 300 bases. A genome blanketed with millions of these markers, the reasoning went, would enable researchers to compare which SNPs predominate in people with a certain disease. Those that do may point to a disease mutation on nearby DNA that is inherited along with the SNP.
Over the past few years, a public-private consortium has deposited some 2.4 million unique SNPs in a public database. Geneticists everywhere are using them. But parsing millions of SNPs to find a few implicated in disease can be challenging-and can cost a fortune. Genotyping, or identifying which bases a SNP can be, costs about 30 cents per SNP, making large disease gene studies unaffordable.
Instead of searching for individual SNPs, the HapMap focuses on patterns of a few SNPs that define each haplotype. If a specific haplotype is more common among those with a certain disease, the mutation linked to that disease should be on that same block of DNA. The HapMap is slated to have about 1/20 the number of SNPs in any given region of the genome that a full SNP map would, says Altshuler, vastly reducing the number that need to be analyzed and saving a truckload of money in the process.
If all goes as planned, researchers working with a finished HapMap could do what Whitehead's Daly is now doing. After finding that one haplotype in the region he was studying is about twice as common among those afflicted with Crohn's, he's now scouring that 200,000-base-long stretch of chromosome for a gene or genes that boost susceptibility to the disease.
Since a workshop last summer in Washington, D.C., roughly 40 scientists and ethicists from institutions across the United States, Europe, and Asia have been solidifying plans for the map. They have settled on the populations to study in the largescale map: the two that the Whitehead group identified in last year's Nature paper, and Asians. The game plan, says Lisa Brooks, program director for the genetic variation program at NHGRI, is to pool the DNA of roughly 50 unrelated people in each population and then search for haplotypes across the entire genome.
Before NHGRI had worked out this plan, the Whitehead scientists launched a minihaplotype map study to test the idea, analyzing haplotypes in European Caucasians, Japanese and Chinese, Yorubans, and African Americans. In a paper published online by Science this week (www.sciencexpress.org), they report that their HapMaps, which focused on 0.4% of the genome, showed that between six and eight SNPs can identify a haplotype and that a given stretch of DNA includes one of three to five haplotypes.
To save money and time, HapMap researchers will start with SNPs in the public database, selecting those that provide good coverage across the chromosomes. Then they'll whittle that set down to those found in at least 10% of their sample populations. If there are large gaps on the chromosomes where no SNPs appear, they'll seek additional ones for the HapMap-something Lander predicts will be necessary.
But many questions remain unresolved. A key issue is how many SNPs need to be mapped-in other words, how dense does the map need to be? "A less dense map saves some money [but] takes a little bit of deliberation" to construct, says Pui-Yan Kwok, a geneticist at the University of California, San Francisco. But "some people can't wait" for this deliberation process to unfold. Kwok, who supports the map, is concerned that those assembling it will "use a brute-force genomic approach to just throw a bunch of markers together" when the benefits of that strategy are poorly understood.
